

Prestige BioPharma Participates in CPhI Worldwide 2021 Milan, Italy



[Prestige Biopharma Booth at CPhI 2021]

[10 November 2021] / Prestige BioPharma Limited (PBP), a Singapore-based biopharmaceutical with global presence, announced that PBP will take part in CPhI Worldwide 2021 Milan, Italy.

CPhI is the world's largest biopharmaceutical conference. This year's event will be held on- and offline for the first time since the Covid-19 outbreak.

PBP has set up a separate booth at the convention and prepared various brochures that allow visitors to see the company's innovative biosimilar and new antibody drug pipelines and global-scale vaccine manufacturing capabilities. A lot of participants have submitted meeting requests on PBP's Herceptin® biosimilar, HD201. The company is also planning to actively promote its first-in-class anti-PAUF monoclonal antibody, PBP1510, for the treatment of pancreatic cancer.

PBP's CEO, Dr Lisa S. Park commented, "we have been receiving a lot of inquiries on our antibody drug R&D and vaccine manufacturing capabilities" and "PBP will actively cooperate with the global pharma companies and organisations who can generate synergy in antibody drug and vaccine business.